Merck & Co., Inc.
Merck & Co., Inc. sells prescription pharmaceuticals (including oncology, vaccines, infectious disease, cardiometabolic, and respiratory therapies) to hospitals, healthcare providers, government agencies, wholesalers, and pharmacies via direct sales and distributor networks by developing, manufacturing, and marketing patented medicines and vaccines. Merck & Co., Inc. sells animal health products (veterinary medicines, vaccines, and digital health solutions) to veterinarians and livestock producers via direct sales and distributor networks by providing innovative animal health management and monitoring solutions.
LOCKED
Market: NormalKey Catalysts & Risks
The dominant variable over the next 12 to 36 months is the Keytruda loss-of-exclusivity path: the core compound patent runs out toward the end of the decade, but management has argued that additional method patents could delay biosimilar entry, and it is simultaneously trying to move a large share of patients onto the subcutaneous formulation whose own patents extend further, which is clear upside if it works and equally clear downside if it does not. The second driver is the launch slate, where the subcutaneous conversion, an oral lipid-lowering medicine, the pulmonary arterial hypertension drug Winrevair and the COPD therapy Ohtuvayre carry near-term commercial momentum; most now depend on payer coverage and reimbursement timing rather than remaining clinical risk, so access milestones matter more than data readouts. The third is business development, where management has said it remains willing to fund further large transactions and has raised its long-term revenue ambition for new growth drivers, a genuinely two-sided catalyst that can add durable growth while bringing financing cost, integration risk and periodic accounting charges. Government price setting for Keytruda is a timing-specific negative that lands near the end of this window and, per the filings, sits alongside broader cost-containment pressure from payers and governments. Timing is disclosed only coarsely and much of this reads from company commentary and trade press, so precise event dates should not be relied upon.
Merck's economics remain concentrated in a single oncology product that faces loss of exclusivity toward the end of the decade, and its own filings state that government and third-party cost-containment measures will continue to pressure sales and profits across the business. The main bridge strategy depends on converting patients to the subcutaneous formulation, which is the subject of active patent litigation with Halozyme over the enabling technology, including an adverse interim ruling in Germany reported by trade press, so an unfavourable outcome could remove much of the intended protection; this risk is documented mainly through media reporting rather than through a filing. US drug-pricing legislation that subjects high-spending medicines to government-negotiated prices is a structural constraint that can compress realised pricing independently of biosimilar entry. These are not near-term liquidity issues, but together they limit how much durability the market is likely to underwrite in the franchise, which is a plausible source of a persistent valuation discount over the next 12 to 36 months.
Research refreshed: 2nd of October 2026
KPIs and Peer Benchmarks
| EV | P/E | Net Debt/EBIT | Revenue Growth | |
|---|---|---|---|---|
| AbbVie Inc. (ABBV) | 529B | 74.04 | 3.40 | 8.6% |
| Amgen Inc. (AMGN) | 261B | 24.85 | 3.42 | 9.9% |
| AstraZeneca… (AZN) | 274B | 23.65 | 1.98 | 8.6% |
| Bristol-Mye… (BMY) | 159B | 13.47 | 2.47 | -0.2% |
| Gilead Scie… (GILD) | 207B | N.M. | N.M. | 2.4% |
| GSK plc (GSK) | 115B | 14.96 | 1.89 | 4.1% |
| Johnson & J… (JNJ) | 646B | 29.60 | 1.09 | 6.0% |
| Eli Lilly a… (LLY) | 1.12T | 38.24 | 1.16 | 44.7% |
| Novo Nordis… (NVO) | 181B | 9.49 | 0.67 | 6.4% |
| Novartis AG (NVS) | 308B | 21.31 | 2.54 | 6.0% |
| Pfizer Inc. (PFE) | 221B | 36.73 | 3.89 | -1.6% |
| Sanofi (SNY) | 115B | 21.65 | 1.71 | 5.5% |
| Merck & Co.… (MRK) | 403B | 114.52 | 4.26 | 1.2% |
AI Opinion
Fundamentals
Commercial resilience and pipeline progress are real, but insufficient to justify $143.795. Q2 KEYTRUDA sales of $8.4B represented roughly 51% of revenue; WINREVAIR grew 75% to $588M and WELIREG grew 67% to $271M, demonstrating diversification progress from a smaller base. The earnings call materially qualifies the fundamental report's deterioration narrative: a disclosed $5.7B one-time Terns charge explains substantial Q2 earnings weakness. Nevertheless, modest underlying growth, acquisition execution risk and approaching 2028 KEYTRUDA exclusivity loss constrain the 12-month upside case.
Peer Comparison
MRK exceeds only approximately 16.7% of 12 peers on combined growth and quality. Strong cash margins do not establish superior capital efficiency or justify a premium. No reliable peer valuation is supplied; healthcare's below-historical-median PE is not evidence that MRK is inexpensive.
Macro Environment
The 5.24% Treasury yield limits support for valuation expansion, while weaker healthcare short-term breadth is contextual rather than company-specific evidence. Approximately 43.7% international revenue creates currency sensitivity; the earnings call identifies roughly one percentage point of FY2026 revenue growth and $0.15 EPS benefit from FX, but these assumptions cannot establish a continuing tailwind. Drug-pricing policy and access requirements could affect LIPFENDRA commercialization and U.S. profitability.
Key Metrics
Revenue growth approximately 4.6%, ROIC 5.62%, asset turnover 0.51x and FCF margin 24.13% indicate stronger cash generation than capital productivity. Historical EV/EBITDA is 22.636x; guarded historical fair values of $71.90-$101.57 signal substantial valuation risk, not a precise 12-month target. The model's divergence cap and accounting distortions reduce its reliability, but current fundamentals do not demonstrate sufficient improvement to dismiss it. Trailing dividend yield is approximately 2.36%.
Insider Activity
No trades in the latest 30 days provide no current directional signal. Approximately $72.02M of older officer sales, including the CEO, modestly reinforces caution; derivative inflows associated with several transactions limit bearish interpretation. Insider activity is confirmatory, not a catalyst.
Income Statement
Q2 revenue increased 5% to $16.6B; raised FY2026 guidance implies only 2%-4% revenue growth to $66.3B-$67.3B. Guided EPS of $2.66-$2.76 includes a $2.31-per-share upfront acquisition charge, so headline earnings multiples overstate recurring valuation pressure. However, inventory reserves reduced non-GAAP gross margin by 1.1 percentage points to 81.1%, while moderating U.S. KEYTRUDA growth and unfavorable channel comparisons weaken near-term operating momentum. Do not assume all elevated R&D is temporary.
Cash Flow
TTM OCF of $19.97B and FCF of $16.06B provide genuine financial support; FCF equals approximately 4.39% of supplied market capitalization. OCF covers $3.90B capex and $8.30B dividends, but $27.30B investing outflows plus repurchases exceed internally generated cash. Other noncash adjustments of $13.53B and a $2.44B working-capital outflow warrant monitoring; accounting addbacks alone do not invalidate cash generation.
Balance Sheet
Debt of $53.91B against $7.14B cash and short-term investments implies $46.77B net debt. TTM net debt issuance of $18.64B, declining equity and goodwill/intangibles at 35.87% of assets increase dependence on successful acquisitions. Management's investment-grade commitment supports financial flexibility, but does not offset the need for cash rebuilding and deleveraging.